Decoquinate-Based Products Market Overview
The Decoquinate-Based Products Market size is estimated to reach $2.1 billion by 2027, growing at a CAGR of 3.6% during the forecast period 2022-2027. Decoquinate-Based products are principally utilized in veterinary medicine. Decoquinate uses include application in cattle for the avoidance of coccidiosis in either ruminating or nonruminating calves, young sheep, goats or broilers brought about by Eimeria spp. It is also utilized to treat sarcocystosis myositis in dogs. Treatment of hepatozoonosis in dogs involves decoquinate blended in food at a dose of 10 to 20 mg/kg provided twice every day as an adjunct therapy to initial TCP or ponazuril treatment for at least 2 years to assist in averting relapse. The successful application of decoquinate without negative impacts to avert relapses in dogs incessantly infected with Hepatozoan americanum is set to drive the Decoquinate-Based Products Market. The growing application of decoquinate in dogs as the prophylactic treatment for coccidiosis and hepatozoonosis is set to propel the growth of the Decoquinate-Based Products Industry during the forecast period 2022-2027. This represents the Decoquinate-Based Products Industry Outlook.
Decoquinate-Based Products Market Report Coverage
The “Decoquinate-Based Products Market Report - Forecast (2022-2027)” by IndustryARC, covers an in-depth analysis of the following segments in the Decoquinate-Based Products Market.
by Type of Formulation: Powder, Tablet and Nanoparticles.
by Distribution Channel: Veterinary Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.
by Geography: North America (the US, Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest Of The World (the Middle East and Africa).
- Geographically, North America (Decoquinate-Based Products market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the enormous cattle population requiring decoquinate uses in the North American region.
- The Decoquinate-Based Products Market growth is being driven by the surging decoquinate uses in veterinary medicine. However, decoquinate is not efficient for treating clinical coccidiosis and has no productiveness against adult coccidia, which are some of the major factors hampering the growth of the Decoquinate-Based Products Market.
- The Decoquinate-Based Products Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Decoquinate-Based Products Market report.
Decoquinate-Based Products Market: Market Share (%) by Region, 2021
Decoquinate-Based Products Market Segment Analysis - by Type of Formulation
The Decoquinate-Based Products Market based on the type of formulation can be further segmented into Powder, Tablet and Nanoparticles. The Powder Segment held the largest share of the Decoquinate-Based Products market in 2021. This growth is fueled by the surging application of powdered decoquinate because of its effortless application. The capability of powdered decoquinate-Based products to effortlessly be included in animal feed and help in the medication being absorbed into the body of the animal at an accelerated speed is further propelling the growth of the Powder segment.
Furthermore, the Nanoparticle segment is estimated to grow with the fastest CAGR of 4.5% during the forecast period 2022-2027 owing to the additional benefits offered by nanoparticles over the powder formulation with the tiny size of nanoparticles making it, even more, easier for nanoparticles to be absorbed into the body of the animal.
Decoquinate-Based Products Market Segment Analysis - by Distribution Channel
The Decoquinate-Based Products Market based on distribution channels can be further segmented into Veterinary Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. The Veterinary Hospital Pharmacies Segment held the largest share of the Decoquinate-Based Products market in 2021. This growth is driven by the surging availability of decoquinate-Based products in veterinary hospital pharmacies. Decoquinate is utilized to treat sarcocystosis myositis in dogs. The soaring application of decoquinate-Based products in veterinary medicine is further propelling the growth of this segment.
Furthermore, the Online Pharmacies segment is estimated to grow with the fastest CAGR of 4.9% during the forecast period 2022-2027 due to the effortless accessibility of online websites stocking veterinary medications. These are conveniently available to buyers at the click of a mouse with the ease of application for special orders with online pharmacies.
Decoquinate-Based Products Market Segment Analysis - by Geography
North America (Decoquinate-Based Products Market) dominated the market with 33% of the overall market in 2021. The growth of this region is driven by the powerful economic conditions in the North American region. The increasing predominance of sarcocystosis myositis in dogs is further propelling the growth of the Decoquinate-Based Products Industry, thereby contributing to the Decoquinate-Based Products Industry Outlook, in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is fueled by factors like the surging consciousness regarding the advantages of decoquinate amidst cattle and poultry breeders in the Asia-Pacific region. The soaring production of decoquinate is further fueling the progress of the Decoquinate-Based Products Market in the Asia-Pacific region.
Decoquinate-Based Products Market Drivers
The Surging Significance of Decoquinate:
Decoquinate belongs to the therapeutic class of Antiprotozoal/Coccidiostat (Systemic Drug). Decoquinate usage involves its labeled application in cattle for the avoidance of coccidiosis. The morbidity rate of coccidiosis is high. However, the rate of clinical disease is 5 to 10%. Decoquinate is a 4-hydroxy quinolone agent that possesses anticoccidial activity. Decoquinate operates on the sporozoite phase of the life cycle. The sporozoite seemingly can still pierce the host intestinal cell. However, further, development is interrupted. The mechanism of action for decoquinate is to disorganize electron transport in the mitochondrial cytochrome system of coccidia. The surging significance of Decoquinate is therefore fueling the growth of the Decoquinate-Based Products Market during the forecast period 2022-2027.
Recommended Treatment Involving Decoquinate for American Canine Hepatozoonosis:
While utilizing Decoquinate for American canine hepatozoonosis, it is important to acquire decoquinate 6% (27.2 grams/lb) powder. Presently, the Companion Animal Parasite Council (CAPC) (www.capcvet.org) suggests that American canine hepatozoonosis patients accept oral treatment with either a triple combination (TCP) of trimethoprim-sulfadiazine 15 mg/kg every 12 hours, clindamycin 10 mg/kg every 8 hours and pyrimethamine 0.25 mg/kg every 24 hours or ponazuril 10 mg/kg every 12 hours for 14 days succeeded by 2 years of every 12 hours decoquinate administration 10–20 mg/kg PO mixed in food. The recommended treatment involving decoquinate for American Canine Hepatozoonosis is therefore driving the growth of the Decoquinate-Based Products Industry. This contributes to the Decoquinate-Based Products Industry Outlook during the forecast period 2022-2027.
Decoquinate-Based Products Market Challenge
Side Effects of Decoquinate:
The level of medicating ingredient in a complete feed is 20 mg/kg (0.003%) of Decoquinate in the complete feed. Decoquinate is not approved by U.S. Food and Drug Administration (FDA) for application in animals generating milk for food or in laying chickens. Side effects are uncommon. However, they must not be utilized in animals that are allergic to it or to treat coccidia infections. Decoquinate needs to be applied as a preventive measure only. If an adverse reaction happens, it is important to call the veterinary office. These issues are thus hampering the growth of the Decoquinate-Based Products Market.
Decoquinate-Based Products Industry Outlook
Novel product launches, mergers and acquisitions, regional expansions and R&D activities are key strategies adopted by players in the Decoquinate-Based Products Market. The top 10 companies in the Decoquinate-Based Products market are:
- Alpharma (a subsidiary of Pfizer Inc.)
- Laboratories Biové
- Pharmacia & Upjohn Company
- Sogeval Laboratories
- Zoetis U.S.
- Hangzhou Haerxi Animal Husbandry Technology co. Ltd,
- Shandong Xinde Technology Co., Ltd.
- Hebei Huabang Biological Technology Co. Ltd.
- In August 2022, it was reported that the anticipated Merck & Co. acquisition of Seagen would be the biggest pharmaceutical acquisition since 2020 if completed. Introductory indications that Merck was waiting to gain the firm surfaced early last month. However, the two firms are yet to make a declaration.
- In April 2021, Merck declared the favorable closing of the cash tender offer, by way of a subsidiary. This was performed for all of the outstanding shares of typical stock of Pandion Therapeutics, Inc. This was carried out at a purchase price of $60 per share.
- In June 2020, Merck declared the completion of the acquisition of Themis. Themis was a privately-held firm directed at vaccines and immune-modulation therapies for infectious ailments and cancer. Milestone echoes Merck’s dedication to expediting the SARS-CoV-2 vaccine program.
Report Code: HCR 0058
Report Code: HCR 0438
Report Code: HCR 0875